Search

Your search keyword '"Chandra, Praveen"' showing total 234 results
Start Over Author "Chandra, Praveen"

Refine your results

more »

more »

more »

more »
234 results on '"Chandra, Praveen"'

3. Safety and effectiveness of the novel Myval Octacor transcatheter heart valve in severe, symptomatic aortic valve stenosis — A real-world Indian experience (The OCTACOR India Study)

Author

Jose, John, Mandalay, Asishkumar, Cholenahally, Manjunath N., Khandenahally, Ravindranath S., Budnur, Srinivas C., Parekh, Maulik, Rao, Ravinder S., Seth, Ashok, Chandra, Praveen, Kapoor, Rajneesh, Agarwal, Praveer, Mathur, Atul, Kumar, Vijay, Kanchanahalli, Sadananda S., Mullasari, Ajith S., Subban, Vijayakumar, Khanolkar, Uday B., Mehrotra, Sanjay, Chopra, Manik, Jain, Rajendra K., Mehta, Haresh, Gupta, Rahul, Kumar, Viveka, Raghuraman, Bagirath, Shastri, Naman, Elzomor, Hesham, Soliman, Osama, and Gunasekaran, Sengottuvelu

Published
2024
Full Text
View/download PDF

4. Angiographic quantification of aortic regurgitation following myval octacor implantation; independent core lab adjudication

Author

Elkoumy, Ahmed, Jose, John, Gunasekaran, Sengottuvelu, Kumar, Asish, Srinivas, B.C., Manjunath, C.N., Ravindranath, K.S., Parekh, Maulik, Chandra, Praveen, Kapoor, Rajneesh, Abdelshafy, Mahmoud, Seth, Ashok, Agrawal, Praveer, Mathur, Atul, Rao, Ravindra Singh, Elzomor, Hesham, Sadanada, K.S., Kumar, Vijay, Arsang-Jang, Shahram, Mehrotra, Sanjay, Raghuraman, Bagirath, Khanolkar, Uday, Premchand, Rajendra Kumar, Chopra, Manik, Krishna, Prem, Mehta, Haresh, Gupta, Rahul, Kumar, Viveka, Senguttuvan, Nagendra Boopathy, Baumbach, Andreas, Serruys, Patrick W., and Soliman, Osama

Published
2023
Full Text
View/download PDF

5. Effectiveness and safety of optical coherence tomography-guided PCI in Indian patients with complex lesions: A multicenter, prospective registry

Author

Chandra, Praveen, Sethuraman, Selvamani, Roy, Sanjeeb, Mohanty, Arun, Parikh, Keyur, Charantharalyil Gopalan, Bahuleyan, Sahoo, Prasant Kumar, Kasturi, Sridhar, Shah, Vijay Trambaklal, Kumar, Viveka, Pinto, Brian, Rath, Pratap Chandra, Yerramareddy, Vijayachandra Reddy, Davidson, Deepak, Navasundi, Girish B., Subban, Vijayakumar, Livingston, Nandhini, Rajaraman, Deva Preethi, Narang, Manish, West, Nick E.J., and Mullasari, Ajit

Published
2023
Full Text
View/download PDF

9. Current practices of Asia-Pacific cardiologists in the utilization of bioresorbable scaffolds

Author

Chanana, B.B., Chandra, Praveen, Cheng, Jack Jun, Dick, Ron, Gwon, Hyeon-Cheol, Hiremath, M.S., Huan, Do Quang, Jeamanukoolkit, Anuruck, Jiang, Tiemin, Kwok, On-Hing, Lim, Michael C.L., Low, Adrian F., Mathew, Rony, Mathew, Samuel K., McClean, Dougal, Nakamura, Sunao, Nguyen, Michael, Qiao, Shubin, Santoso, Teguh, Saxena, Sudheer, Schultz, Carl, Sengottuvelu, G., Seth, Ashok, Simonton, Charles A., Soo, Chee Siong, Sudhir, Krishnankutty, Tsai, Cheng-Ting, Wasan, Udayachalerm, Whelan, Alan, Wong, Chris, and Yap, Yee Guan

Published
2016
Full Text
View/download PDF

10. Role of Iron Therapy in Heart Failure: A Consensus Statement from India

Author

Chopra, H K, primary, Wander, G S, additional, Nair, Tiny, additional, Ponde, C K, additional, Nanda, Navin C, additional, Narula, Jagat, additional, Ray, Saumitra, additional, Venugopal, K, additional, Iyengar, S S, additional, Kasliwal, R R, additional, Chandra, Praveen, additional, Prakash, Sunil, additional, Bansal, Sandeep, additional, Rana, D S, additional, Kerkar, Prafulla, additional, Dasbiswas, Arup, additional, Sawhney, JPS, additional, Shanmungasundram, S, additional, Kumar, Viveka, additional, Vijayalakshmi, I B, additional, Pancholia, A K, additional, Sharma, Vinod, additional, Kapoor, Aditya, additional, Swami, Onkar C, additional, Isser, H S, additional, Rastogi, Vishal, additional, Arora, Y K, additional, Omar, Ashok K, additional, Sathe, Sunil, additional, Rajput, Rajeeve, additional, Prabhakar, D, additional, Paul, G J, additional, Jagia, Priya, additional, Malhotra, Poonam, additional, Suryaprakash, G, additional, Mittal, Vinod, additional, Jagia, Manish, additional, Jabir, A, additional, Mishra, S S, additional, Routray, S N, additional, Sinha, Ajay K, additional, Bhargava, Mohan, additional, Mahmood, Kiran, additional, Bhatia, Mona, additional, Kalra, Pramila, additional, Katyal, V K, additional, Tandon, Rohit, additional, Grover, Rahul, additional, Chhabra, Abhinav, additional, and Shastry, N R, additional

Published
2023
Full Text
View/download PDF

11. The Power and Promise of Angiotensin Receptor Neprilysin Inhibitor (ARNI) in Heart Failure Management: National Consensus Statement

Author

Chopra, H K, primary, Wander, G S, additional, Ponde, C K, additional, Nanda, Navin C, additional, Khullar, Dinesh, additional, Venugopal, K, additional, Ray, Saumitra, additional, Nair, Tiny, additional, Rana, D S, additional, Kher, Vijay, additional, Sawhney, J P S, additional, Kasliwa, R R, additional, Jabir, A, additional, Chakraborty, Rabin, additional, Chandra, Praveen, additional, Bansal, Sandeep, additional, Kumar, Viveka, additional, Pancholia, A K, additional, Kapoor, Aditya, additional, Prakash, Sunil, additional, Saxena, Anil, additional, Rastogi, Vishal, additional, Sharma, Vinod, additional, Arora, Y K, additional, Dasbiswas, Arup, additional, Bhargava, Mohan, additional, Jaswal, Aparna, additional, Bhargava, K, additional, Bhatia, Mona, additional, Omar, A K, additional, Khanna, N N, additional, Passey, Rajiv, additional, Bhalla, Dilip, additional, Vijayalakshmi, I B, additional, Bhalla, A K, additional, Moorthy, Asha, additional, Isser, H S, additional, Mishra, S S, additional, Routray, S N, additional, Tandon, Vivek, additional, Sinha, Ajay, additional, Bansal, Manish, additional, Jain, Praveen, additional, Hotchandani, Ramesh, additional, Jain, Dharmendra, additional, Katyal, V K, additional, Gulati, Sanjiv, additional, Tandon, Rohit, additional, Jaggi, Shalini, additional, Sehgal, Blessy, additional, Gupta, Vitull, additional, Mehrotra, Rahul, additional, Krishnamani, N C, additional, Pathak, S N, additional, Yadav, M S, additional, Chawla, Rajeev, additional, Pal, Jyotirmoy, additional, Chatterjee, Nandini, additional, S Samajdar, Shambo, additional, and Shastry, N R, additional

Published
2023
Full Text
View/download PDF

13. Bempedoic Acid for Management of Dyslipidemia from an Indian Perspective: An Expert Consensus Report

Author

Maddury, Srinivasa Rao, primary, Sawhney, Jps, additional, Kerkar, Prafulla G, additional, Jain, Piyush, additional, Chandra, Praveen, additional, Sashikant, T., additional, Shah, Jay, additional, Makkar, Jitendra Singh, additional, Benjamin, Bino, additional, Daniel, Rachel, additional, Solanki, Dharmesh, additional, Chandorkar, A.B., additional, Yugandhar, B, additional, and Sharma, Kamal, additional

Published
2022
Full Text
View/download PDF

19. Clinical expert consensus document on the use of percutaneous left ventricular assist devices during complex high-risk PCI in India using a standardised algorithm

Author

Tayal, Rajiv, primary, Kalra, Sanjog, additional, Seth, Ashok, additional, Chandra, Praveen, additional, Sohal, Sumit, additional, Punamiya, Kirti, additional, Rao, Ravinder, additional, Rastogi, Vishal, additional, Kapardhi, P.L.N., additional, Sharma, Sanjeev, additional, Kumar, Prathap, additional, Arneja, Jaspal, additional, Mathew, Rony, additional, Kumar, Dilip, additional, Mahesh, N.K., additional, and Trehan, Vijay, additional

Published
2022
Full Text
View/download PDF

25. One-year clinical outcomes of BioMatrix™-Biolimus A9™ eluting stent: The e-BioMatrix multicenter post marketing surveillance registry in India

Author

Mehta, Ashwin B., Chandra, Praveen, Dalal, Jamshed, Shetty, Prabhakar, Desai, Devang, Chocklingam, K., Prajapati, Jayesh, Kumar, Pramod, Magarkar, Vilas, Vasawada, Apurva, Goyal, B.K., Kumar, Viveka, Rao, V. Suryaprakash, Babu, Ramesh, Parikh, Pritesh, Kaul, Upendra, Patil, Aruna, Mhetre, Tushar, and Rangnekar, Hrishikesh

Published
2013
Full Text
View/download PDF

27. 30-Day and 1-Year Outcomes With HYDRA Self-Expanding Transcatheter Aortic Valve:The Hydra CE Study

Author

Aidietis, Audrius, Srimahachota, Suphot, Dabrowski, Maciej, Bilkis, Vaildas, Buddhari, Wacin, Cheung, Gary S.H., Nair, Rajesh K., Mussayev, Abdurashid A., Mattummal, Shafeeq, Chandra, Praveen, Mahajan, Ajay U., Chmielak, Zbigniew, Govindan, Sajeev C., Jose, John, Hiremath, Murugesh S., Chandra, Sharad, Shetty, Ranjan, Mohanan, Sandeep, John, John F., Mehrotra, Sanjay, Søndergaard, Lars, Aidietis, Audrius, Srimahachota, Suphot, Dabrowski, Maciej, Bilkis, Vaildas, Buddhari, Wacin, Cheung, Gary S.H., Nair, Rajesh K., Mussayev, Abdurashid A., Mattummal, Shafeeq, Chandra, Praveen, Mahajan, Ajay U., Chmielak, Zbigniew, Govindan, Sajeev C., Jose, John, Hiremath, Murugesh S., Chandra, Sharad, Shetty, Ranjan, Mohanan, Sandeep, John, John F., Mehrotra, Sanjay, and Søndergaard, Lars

Abstract

Objectives: This study sought to evaluate the 30-day and 1-year safety and performance of the Hydra transcatheter aortic valve (THV) (in the treatment of symptomatic severe aortic stenosis in patients at high or extreme surgical risk. Background: The Hydra THV is a novel repositionable self-expanding system with supra-annular bovine pericardial leaflets. Methods: The Hydra CE study was a premarket, prospective, multicenter, single-arm study conducted across 18 study centers in Europe and Asia-Pacific countries. The primary endpoint was all-cause mortality at 30 days. All endpoints were adjudicated by an independent clinical events committee. Results: A total of 157 patients (79.2 ± 7.1 years of age, 58.6% female; Society of Thoracic Surgeons score 4.7 ± 3.4%) were enrolled. Successful implantation was achieved in 94.3% cases. At 30 days, there were 11 (7.0%) deaths, including 9 (5.7%) cardiovascular deaths, of which 5 (3.2%) were device related. At 1 year, there were 23 (14.6%) deaths, including 13 (8.3%) cardiovascular deaths. At 30 days, there were significant improvement of effective orifice area (from 0.7 ± 0.2 cm2 to 1.9 ± 0.6 cm2) and mean aortic valve gradient (from 49.5 ± 18.5 mm Hg to 8.1 ± 3.7 mm Hg), which were sustained up to 1 year. Moderate or severe paravalvular leak was observed in 6.3% of patients at 30 days and 6.9% of patients at 1 year. The rate of new permanent pacemaker implantation was 11.7% at 30 days and 12.4% at 1 year. Conclusions: The Hydra CE study demonstrated that transcatheter aortic valve replacement with Hydra THV offered favorable efficacy at 1 year, providing large effective orifice area and low transvalvular gradient as well as acceptable complication rates with regard to new permanent pacemaker and paravalvular leak. (A Clinical Evaluation of the HYDRA Self Expanding Transcatheter Aortic Valve; NCT02434263)

Published
2022

29. CRT-100.98 Sirolimus-Eluting Balloon With a Micro-Reservoir-Based Technology for the Treatment of De Novo Coronary Lesions – Subgroup Analysis of a Prospective, Multi-Center, Pivotal Single-Arm Trial

Author

Costa, Ricardo A., primary, Mandal, Sankar C., additional, Hazra, Prakash K., additional, Chopda, Manoj, additional, Chandra, Praveen, additional, Damiani, Lucas P., additional, Abizaid, Alexandre, additional, and Hiremath, Shirish, additional

Published
2022
Full Text
View/download PDF

33. 30-Day and 1-Year Outcomes With HYDRA Self-Expanding Transcatheter Aortic Valve

Author

Aidietis, Audrius, primary, Srimahachota, Suphot, additional, Dabrowski, Maciej, additional, Bilkis, Vaildas, additional, Buddhari, Wacin, additional, Cheung, Gary S.H., additional, Nair, Rajesh K., additional, Mussayev, Abdurashid A., additional, Mattummal, Shafeeq, additional, Chandra, Praveen, additional, Mahajan, Ajay U., additional, Chmielak, Zbigniew, additional, Govindan, Sajeev C., additional, Jose, John, additional, Hiremath, Murugesh S., additional, Chandra, Sharad, additional, Shetty, Ranjan, additional, Mohanan, Sandeep, additional, John, John F., additional, Mehrotra, Sanjay, additional, and Søndergaard, Lars, additional

Published
2022
Full Text
View/download PDF

35. Clinical characteristics and outcomes after unplanned intraaortic balloon counterpulsation in the Counterpulsation to Reduce Infarct Size Pre-PCI Acute Myocardial Infarction trial

Author

Kohl, Louis P., Leimberger, Jeffrey D., Chiswell, Karen, Jones, Schuyler W., Thiele, Holger, Smalling, Richard W., Chandra, Praveen, Cohen, Marc, Perera, Divaka, Chew, Derek P., French, John K., Blaxil, Jonathan, Kumar, Sreenivas A., Ohman, Magnus E., and Patel, Manesh R.

Published
2016
Full Text
View/download PDF

42. Clinical evaluation of the Hydra self-expanding transcatheter aortic valve:6 month results from the GENESIS trial

Author

Chandra, Praveen, Jose, John, Mattummal, Shafeeq, Mahajan, Ajaykumar U., Govindan, Sajeev C., Makhale, Chandrashekhar N., Chandra, Sharad, Shetty, Ranjan, Mohanan, Sandeep, John, John F., Mehrotra, Sanjay, Søndergaard, Lars, Chandra, Praveen, Jose, John, Mattummal, Shafeeq, Mahajan, Ajaykumar U., Govindan, Sajeev C., Makhale, Chandrashekhar N., Chandra, Sharad, Shetty, Ranjan, Mohanan, Sandeep, John, John F., Mehrotra, Sanjay, and Søndergaard, Lars

Abstract

Objectives: To evaluate the safety and performance of the Hydra transcatheter aortic valve (THV) in the treatment of symptomatic severe aortic stenosis in patients at high or extreme surgical risk. Background: The Hydra THV (Vascular Innovations Co. Ltd., Nonthaburi, Thailand) is a novel flexible repositionable self-expanding system with supra-annular bovine pericardial leaflets, available in three sizes, covering aortic annuli between 17 and 27 mm. Methods: The GENESIS trial was a prospective, multi-center, single-arm, 6 month follow-up study conducted in India. The primary performance endpoint was device success defined as per VARC-II criteria at 30 days. The primary safety endpoint was all-cause mortality at 30 days. All endpoints were adjudicated by an independent clinical events committee. Results: Forty high-risk patients (74.5 ± 6.7 years, 60% men; STS Score:5.6 ± 4.2%) were enrolled in 11 centres. Device success was achieved in 92.5%. The effective orifice area improved from 0.7 ± 0.2 to 2.3 ± 0.6 cm2 at 30 days and to 2.2 ± 0.7 cm2 at 6 months (p <.0001). Mean aortic valve gradient decreased from 53.5 ± 18.1 to 8.9 ± 4.9 mmHg at 30 days and to 7.6 ± 2.7 mmHg at 6 months (p <.0001). The rate of new permanent pacemaker implantation was 7.5% at 30 days, and no patient had more than mild paravalvular leak at 6 months. The 30 days and 6 month all-cause mortality was 10.0 and 17.5%, cardiovascular mortality 7.5 and 7.5%, device-related mortality 5.0 and 5.0%, respectively. No patients had stroke up to 6 months. Conclusions: The GENESIS trial demonstrated high efficacy of the self-expanding Hydra THV. The cardiovascular mortality rate of 7.5% may partly be explained by the inclusion of some centres with no or limited previous experience in transcatheter aortic valve implantation.

Published
2021

43. Advances in CLOT Treatment (ACT): A Textbook of Cardiology

Author

Chopra, HK, Nanda, Navin C, Narula, Jagat, Wander, GS, Manjunath, CN, Chandra, Praveen, Kumar, Viveka, Ponde, CK, Pancholia, AK, Chopra, HK, Nanda, Navin C, Narula, Jagat, Wander, GS, Manjunath, CN, Chandra, Praveen, Kumar, Viveka, Ponde, CK, and Pancholia, AK

Abstract

It is the first publication of its kind in the form of a textbook of cardiology from India to the world. Over 300 contributors from India and abroad have contributed their prestigious chapters in this book, focuses on every aspect of clot management with enormous information about advances in clinical approach, imaging including echocardiography, multimodality imaging, drug, mechanical and surgical interventions for better patient care with clot inflicted morbidity and mortality reduction in various clinical situations and has tremendous innovative and research potential of understanding advances and innovations in clot care for the undergraduates, postgraduates, practicing cardiologists, endocrinologists, nephrologists, neurologists, critical care, pulmonologists, pediatricians, pediatric surgeons, physicians, cardiovascular surgeons, imaging experts and nutritionists, etc. The book including 36 sections and 158 chapters.

Published
2023

44. Clinical evaluation of the Hydra self‐expanding transcatheter aortic valve: 6 month results from the GENESIS trial

Author

Chandra, Praveen, primary, Jose, John, additional, Mattummal, Shafeeq, additional, Mahajan, Ajaykumar U., additional, Govindan, Sajeev C., additional, Makhale, Chandrashekhar N., additional, Chandra, Sharad, additional, Shetty, Ranjan, additional, Mohanan, Sandeep, additional, John, John F., additional, Mehrotra, Sanjay, additional, and Søndergaard, Lars, additional

Published
2021
Full Text
View/download PDF

45. 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region

Author

Tan, Jack WC, primary, Chew, Derek P, additional, Abdul Kader, Muhamad Ali SK, additional, Ako, Junya, additional, Bahl, Vinay K, additional, Chan, Mark, additional, Park, Kyung Woo, additional, Chandra, Praveen, additional, Hsieh, I-Chang, additional, Huan, Do Quang, additional, Johar, Sofian, additional, Juzar, Dafsah Arifa, additional, Kim, Byeong-Keuk, additional, Lee, Cheol Whan, additional, Lee, Michael Kang-Yin, additional, Li, Yi-Heng, additional, Almahmeed, Wael, additional, Sison, Eric Oliver, additional, Tan, Doreen, additional, Wang, Yu-Chen, additional, Yeh, Shiuan Jong, additional, and Montalescot, Gilles, additional

Published
2021
Full Text
View/download PDF

48. Advances in Statin Therapy & Beyond in CVD (ASTC)

Author

Chopra, HK, Nanda, Navin C, Narula, Jagat, Wander, GS, Manjunath, CN, Chandra, Praveen, Kumar, Viveka, Ponde, CK, Pancholia, AK, Chopra, HK, Nanda, Navin C, Narula, Jagat, Wander, GS, Manjunath, CN, Chandra, Praveen, Kumar, Viveka, Ponde, CK, and Pancholia, AK

Subjects
Cardiovascular system--Diseases--Treatment, Statins (Cardiovascular agents)
Abstract

This book covers the role of statins in all cardiovascular ailments, from prevention to disease management, and brought you the evolving pharmacological interventions. It is an attempt to interference with the cholesterol synthesis pathways through statins and bempedoic acid, and blocking PCSK9 from binding to LDL receptor by intercepting with antibodies or nipping them early by intracellular inhibition of the translation of message to proteins, the monograph brings into focus the ultimate importance of LDL receptors.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results